NCT02314481View on ClinicalTrials.gov

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 12, 2017

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

MPDL3280A

Intravenous (IV) infusion, as monotherapy of in combination with chemotherapy

DRUG

Vemurafenib

Film coated tablet

DRUG

Alectinib

capsule

DRUG

Trastuzumab emtansine

Powder for concentrate for solution for infusion

Trial Locations (1)

Unknown

Univeristy College London Hospital, London

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

University College, London

OTHER